Epithelioid Sarcoma

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Epithelioid Sarcoma is an early-stage landscape with 3 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

50/100

Pipeline

Programs by Phase

Preclinical2

TAZEMETOSTAT

Epizyme, Inc.

VIA Combination Treatment

Peking University People's Hospital

Phase 11

Doxorubicin HCL

Memorial Sloan Kettering Cancer Center

Phase 2

No programs

Phase 3

No programs

Approved

No programs

Analysis

Trial Status

clinical trials

No longer available2 · 50%

Terminated1 · 25%

Withdrawn1 · 25%

Clinical Trials

Trial Activity

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Terminated·EEpizyme, Inc.·Phase 1·NCT04204941·25 enrolled

Irinotecan and Anlotinib for Epithelioid Sarcoma

Withdrawn·PPeking University People's Hospital·N/A·NCT05656222

Tazemetostat Expanded Access Program for Adults With Solid Tumors

No longer available·EEpizyme, Inc.·N/A·NCT03874455

Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

No longer available·EEpizyme, Inc.·N/A·NCT04225429

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)